MAP Pharmaceuticals, Inc. 4
4 · MAP Pharmaceuticals, Inc. · Filed Mar 8, 2010
Insider Transaction Report
Form 4
PERSEUS SOROS PARTNERS LLC
10% Owner
Transactions
- Sale
Common Stock
2010-03-04$14.15/sh−677$9,580→ 2,830,785 total(indirect: See Footnotes) - Sale
Common Stock
2010-03-05$13.95/sh−4,616$64,393→ 2,826,169 total(indirect: See Footnotes)
Footnotes (5)
- [F1]The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F2]The securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros") and Perseus-Soros Partners, LLC ("Perseus-Soros Partners"). Perseus-Soros Partners is the general partner of Perseus-Soros.
- [F3]Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners owns directly 4,616 shares of the Issuer's Common Stock.
- [F4]The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock.